SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001493152-24-031393 from AIxCrypto Holdings, Inc. (AIXC)

AIxCrypto Holdings, Inc.
Date: Aug. 12, 2024 · CIK: 0001460702 · Accession: 0001493152-24-031393

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-272623

Date
Aug. 12, 2024
Author
UNIVEST SECURITIES, LLC
Form
CORRESP
Company
AIxCrypto Holdings, Inc.

Letter

UNIVEST SECURITIES, LLC

ROCKEFELLER PLAZA 18C

NEW YORK, NY 10019

August 12, 2024

VIA EDGAR CORRESPONDENCE

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

F Street, NE

Washington, D.C., 20549

Re: Qualigen Therapeutics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-272623

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on August 12, 2024, in which we, as placement agent for Qualigen Therapeutics, Inc.’s (the “Company’s”) proposed public offering, joined the Company’s request for acceleration of the effective date of the above-referenced Registration Statement for August 12, 2024 at 4:00 p.m., Eastern Time. The Company is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

If you have any questions regarding the foregoing, please contact our counsel at Sullivan & Worcester LLP, Joseph Segilia, Esq. at 212-660-3027.

Very truly yours,
UNIVEST SECURITIES, LLC

Show Raw Text
CORRESP
1
filename1.htm

UNIVEST
SECURITIES, LLC

75
ROCKEFELLER PLAZA 18C

NEW
YORK, NY 10019

August
12, 2024

VIA
EDGAR CORRESPONDENCE

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, NE

Washington,
D.C., 20549

    Re:
    Qualigen
    Therapeutics, Inc.

    Registration
    Statement on Form S-1, as amended

    File
    No. 333-272623

Ladies
and Gentlemen:

Reference
is made to our letter, filed as correspondence via EDGAR on August 12, 2024, in which we, as placement agent for Qualigen Therapeutics,
Inc.’s (the “Company’s”) proposed public offering, joined the Company’s request for acceleration of the
effective date of the above-referenced Registration Statement for August 12, 2024 at 4:00 p.m., Eastern Time. The Company is no longer
requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration
of the effective date.

If
you have any questions regarding the foregoing, please contact our counsel at Sullivan & Worcester LLP, Joseph Segilia, Esq. at 212-660-3027.

    Very truly yours,

    UNIVEST SECURITIES, LLC

    By:
    /s/
    Bradley Richmond

    Bradley
    Richmond

    COO
    and Head of Investment Banking

    cc:
    Joseph
    Segilia, Esq.

    Sullivan
    & Worcester LLP